Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;28(2):56-62.
doi: 10.1016/j.trre.2013.12.003. Epub 2013 Dec 12.

Bone and mineral disorders after kidney transplantation: therapeutic strategies

Miklos Z Molnar  1 , Mohamed S Naser  2 , Connie M Rhee  3 , Kamyar Kalantar-Zadeh  4 , Suphamai Bunnapradist  5
Affiliations
Review

Bone and mineral disorders after kidney transplantation: therapeutic strategies

Miklos Z Molnar et al. Transplant Rev (Orlando). 2014 Apr.

Abstract

Mineral and bone diseases (MBD) are common in patients with chronic kidney disease who undergo kidney transplantation. The incidence, types and severity of MBD vary according to the duration of chronic kidney disease, presence of comorbid conditions and intake of certain medications. Moreover, multiple types of pathology may be responsible for MBD. After successful reversal of uremia by kidney transplantation, many bone and mineral disorders improve, while immunosuppression, other medications, and new and existing comorbidities may result in new or worsening MBD. Chronic kidney disease is also common after kidney transplantation and may impact bone and mineral disease. In this article, we reviewed the prevalence, pathophysiology, and impact of MBD on post-transplant outcomes. We also discussed the diagnostic approach; immunosuppression management and potential treatment of MBD in kidney transplant recipients.

PubMed Disclaimer

Conflict of interest statement

Relevant Potential Conflict of Interest:

Dr. Kalantar-Zadeh has received grants and/or honoraria from Abbott, Amgen, DaVita, Fresenius-Kabi, Genzyme, Otsuka, and Shire. Drs. Molnar, Naser, Rhee and Bunnapradist report no conflicts of interest.

Figures

Figure 1
Figure 1
Light microscopy (A) and tetracycline labeling (B) pictures of adynamic bone disease in a kidney transplant recipient
Figure 1
Figure 1
Light microscopy (A) and tetracycline labeling (B) pictures of adynamic bone disease in a kidney transplant recipient
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333(3):166–74. Epub 1995/07/20. - PubMed
    1. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis. 1995;26(5):836–44. Epub 1995/11/01. - PubMed
    1. Bonomini V, Feletti C, Di Felice A, Buscaroli A. Bone remodelling after renal transplantation (RT) Adv Exp Med Biol. 1984;178:207–16. Epub 1984/01/01. - PubMed
    1. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int. 1998;53(5):1358–64. Epub 1998/05/09. - PubMed
    1. Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab. 1982;8(2):92–112. Epub 1982/08/01. - PubMed

Publication types